Efficacy and safety of high‐dose glucagon‐like peptide‐1, glucagon‐like peptide‐1/glucose‐dependent insulinotropic peptide, and glucagon‐like peptide‐1/glucagon receptor agonists in type 2 diabetes
Year: 2022
Type: review
Study design: Systematic Review
Source: Diabetes Obesity and Metabolism
DOI: 10.1111/dom.14640
Institutions: University of Antwerp, Antwerp University Hospital
Language: English
Subfield: Endocrinology, Diabetes and Metabolism
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4205614799
